First successful phase 3 trial: bespoke mRNA vaccine cuts melanoma recurrence risk
Competitive_Travel16 · reddit · 2026-10-25
The Guardian reports that a "bespoke" mRNA vaccine significantly reduces the risk of melanoma recurrence or death in a phase 3 clinical trial — the first successful phase 3 trial for an mRNA cancer vaccine, a milestone for the field. Tangential to AI.
More from Research
- CycleDistill: synthetic-data self-distillation lifts Indic MT by 20+ chrF in one cycle — cneuralnetwork · 2026-10-25
- ICLR 2027 still issuing desk rejects as community battles AI slop submissions — Temporary_Switch_339 · 2026-10-25
- TEMPO benchmark: best of 16 retrievers hits only 32.0 NDCG@10; RAG with no retrieval scores higher — mageed · 2026-10-25
- Random speckle spectrometers make some of the best-looking photonic chips — jwt0625 · 2026-10-25
- Studies show the same artwork scores lower when labeled AI-made — bias, not quality — AIandDesign · 2026-10-25
- Anthropic uses Claude to formally verify 100+ real-world open-source libraries in weeks — tianyin_xu · 2026-10-25